← Back

OSR Holdings Inc

OSR Health, Inc. is a healthcare holding company that develops a portfolio of therapies and healthcare solutions across the United States, Europe, and Korea. Its pipeline includes immunotherapy products such as VXM01, an immuno-oncology candidate for glioblastoma that has completed a phase 2 clinical trial, along with preclinical candidates VXM04 for mesothelin, VXM06 for Wilms Tumor Protein (WT1), VXM08 for Carcinoembryonic antigen (CEA), and VXM10 for PD-L1. The company also develops design-augmented (DA) biologics, including DRT-102, a clinical-stage asset for spinal fusion, and DRT-101, a preclinical-stage asset for osteoarthritis, and distributes neurovascular intervention medical devices and systems. Formerly known as OSR Holdings, Inc., it changed its name to OSR Health, Inc. in June 2026, was incorporated in 2020, and is based in Bellevue, Washington.

Price · split & dividend adjusted
News & notes moving OSRH
OSRH▼2

OSR Health Prepares Nasdaq Appeal, Cites $15 Million Put Option

OSR Health, Inc. announced it is preparing a formal appeal to the Nasdaq Independent Hearings Panel after receiving a delisting determination on August 19, with plans to submit its hearing request by August 26. The company also highlighted its $15 million Put Option exercisable against BCM Europe AG from October 29, 2026, at $10.00 per share, which it says reflects a third-party institutional valuation of its VXM01 asset. CEO Peter Hwang stated that the option remains unchanged and that management is in active communication with BCM Europe's Korean end investors regarding settlement capacity. OSR Health's subsidiaries Woori IO and Darnatein will continue development activities, and the company plans to file a registration statement for its CVR program.
OSRH ▼
OSR Health, Inc.·28dRead more →
OSRH▲

OSR Health CEO confirms two subsidiaries in out-licensing talks as Nasdaq deadline looms

OSR Health CEO Peter Hwang reaffirmed confidence in the company's fundamental value and disclosed that two subsidiaries have received inbound inquiries for potential out-licensing of their technologies and products, with one at the preliminary term sheet negotiation phase and the other in early-stage discussions. The announcement comes as the company faces an August 18 deadline for Nasdaq to determine its continued listing status if the stock price has not regained the $1.00 minimum bid requirement. Hwang stated he remains 'all in' as the largest investor, having committed substantial personal capital since inception, and believes the accelerating business development activities will increasingly demonstrate commercial potential. He asked shareholders to remain engaged and supportive during this critical period, emphasizing that the company is doing everything within its control to preserve its Nasdaq listing.
OSRH ▲
ACCESS Newswire·38dRead more →
© 2026 MarketDXAsset